Compare Nokia Corp (NOK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs BIO-TECHNE Corp — how do they compare? Nokia Corp trades at $10.24 (market cap $60.13B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Nokia Corp is far larger — about 5.3× BIO-TECHNE Corp's market cap, and Nokia Corp pays the higher dividend (1.54%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and BIO-TECHNE Corp for 63 Days on average.
| NOK | TECH | |
|---|---|---|
Market Cap | $60.13B | $11.37B |
Volume | 71,806,452 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $16.83 | $72.61 |
52-Week Low | $5.18 | $43.31 |
Typical Hold Time | 66 Days | 63 Days |
Enterprise Value | $58.14B | $11.40B |
Dividend Yield | 1.54% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.14, down 7.57% over the past day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships with Microsoft and ICEYE for AI and satellite communications, driving positive sentiment.
The outlook is supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings, but risks include volatile cash flows and high valuation multiples. Upside potential exists from AI infrastructure demand, while execution and competitive pressures remain key concerns for investors.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
